Brilinta 90mg Tablet 180s

Ticagrelor is an antiplatelet medication used to reduce the risk of heart attack, stroke, and cardiovascular death in people with acute coronary syndrome (ACS) or a history of heart disease. It works by preventing platelets from sticking together, helping maintain smoother blood flow. Doctors commonly prescribe it following stent placement or after a major cardiac event. Taken regularly as advised, it offers strong protection against future heart-related complications.

Ticagrelor is a fast-acting and reversible antiplatelet drug widely used in the management and prevention of serious cardiovascular events. It is typically prescribed for patients who have experienced acute coronary syndrome (including unstable angina, NSTEMI, or STEMI) or those who have undergone coronary stent implantation. By inhibiting platelet activation, Ticagrelor significantly reduces the likelihood of clot formation within arteries, which can otherwise trigger heart attacks or strokes.

Unlike many traditional antiplatelet medicines, Ticagrelor does not require metabolic activation, which allows quicker platelet inhibition and more consistent results. This makes it an important choice for both emergency and long-term treatment strategies.

Doctors usually prescribe Ticagrelor twice daily, along with low-dose aspirin, as part of dual antiplatelet therapy (DAPT). This combination helps keep arteries open, particularly after angioplasty or stent procedures. Patients who take Ticagrelor are advised to be consistent with dosing, as even missed doses can reduce its protective effect. While Ticagrelor offers significant benefits, it may cause side effects such as shortness of breath or an increased risk of bleeding. Regular follow-ups and adherence to medical advice ensure safe and effective use. With proper monitoring, Ticagrelor plays a vital role in improving long-term heart health outcomes and preventing recurrent cardiovascular events.

• Reduces the risk of heart attack in patients with acute coronary syndrome.

• Prevents stroke and cardiovascular death in people with previous heart conditions.

• Helps maintain blood flow in patients who have undergone angioplasty or coronary stent placement.

• Used as part of dual antiplatelet therapy (usually with low-dose aspirin).

• Prevents clot formation in high-risk individuals with unstable angina or prior myocardial infarction.

• Supports recovery and reduces complications after severe cardiac events.

• Provides strong protection against blood clots, helping prevent future heart attacks and strokes.

• Rapid onset of action, offering quicker platelet inhibition compared to many standard antiplatelet medicines.

• Highly effective in emergency cardiac situations, supporting faster stabilisation of patients.

• Reversible platelet inhibition allows doctors greater flexibility in managing or adjusting treatment.

• Offers consistent efficacy, reducing patient-to-patient variability.

• Significantly improves long-term outcomes when used with aspirin in patients with stents or a history of acute coronary syndrome.

• Reduces hospital readmissions by lowering the risk of recurrent cardiac events.

• Supports better long-term cardiovascular health through sustained antiplatelet protection.

• Shortness of breath (dyspnoea)

• Increased risk of bleeding or bruising

• Nosebleeds

• Headache or dizziness

• Gastrointestinal discomfort

• Slow heart rate (rare)

• Elevated uric acid levels

• Mild rash or itching

• Rare but serious internal bleeding (seek urgent help if suspected)

• Take Ticagrelor 90 mg exactly as prescribed by your doctor.

• Usually taken twice daily with or without food.

• Swallow the tablet whole with water; do not crush or chew.

• Take at the same time each day for best results.

• Continue taking even if you feel well unless your doctor advises otherwise.

• Do not stop suddenly, as this increases the risk of clotting.

Ticagrelor works by selectively and reversibly inhibiting the P2Y12 receptor on platelets. This receptor plays a key role in platelet activation and aggregation, which are essential steps in blood clot formation. By blocking this receptor, Ticagrelor prevents platelets from clumping together, thereby reducing the risk of arterial blockages that may trigger a heart attack or stroke.

Unlike some other antiplatelet agents, Ticagrelor does not need metabolic activation by the liver, allowing it to provide rapid, consistent platelet inhibition. Its reversible binding also enables more controlled platelet function recovery when therapy is stopped. Overall, it ensures a steady and reliable reduction in clotting risk, especially in high-risk cardiac patients.

• Always take Ticagrelor with low-dose aspirin unless advised otherwise.

• Never stop the medication suddenly.

• Inform healthcare providers that you’re on Ticagrelor before surgery.

• Use a pill reminder to avoid missed doses.

• Report breathlessness or unusual bleeding promptly.

• Store in a cool, dry place away from moisture.

• Keep away from direct sunlight.

• Do not freeze.

• Keep the tablets in their original packaging.

• Keep out of reach of children.

Ticagrelor does not have major interactions with most foods, but maintaining a consistent eating pattern helps avoid stomach discomfort. Avoid excessive alcohol and grapefruit products, as they may affect how the medicine works.

Avoid:

• Grapefruit juice (may increase blood levels)

• Heavy alcohol consumption

• High-fat meals if they increase gastric discomfort

Safe to Have:

• Normal balanced meals

• Light snacks with the dose if stomach upset occurs

Ticagrelor interacts with several medications, which may increase bleeding risk or alter its effectiveness. Always inform your doctor about all prescription, OTC, and herbal medicines you are taking. Avoid combining with strong CYP3A4 inhibitors or inducers.

Common Interacting Medicines:

• Anticoagulants (warfarin, heparin)

• Other antiplatelets (clopidogrel, prasugrel)

• Strong antifungals (ketoconazole)

• Rifampicin

• Anti-seizure medicines (phenytoin, carbamazepine)

• HIV protease inhibitors

• High-dose aspirin (>300 mg daily)

Ticagrelor should be used with caution in patients with certain medical conditions. Some diseases can increase the risk of complications such as bleeding or breathing problems. Always discuss your medical history with your doctor before starting treatment.

Use with Caution In:

• History of bleeding disorders

• Severe liver impairment

• Asthma or chronic obstructive pulmonary disease (COPD)

• Active peptic ulcer disease

• Very low heart rate or heart conduction problems

The usual recommended dose of Ticagrelor is twice daily, taken approximately 12 hours apart. It is commonly combined with low-dose aspirin (75–100 mg daily). Your doctor may adjust the duration of therapy depending on your condition, response, and risk of bleeding. Do not change the dose on your own.

Taking more than the prescribed dose of Ticagrelor can significantly increase the risk of severe bleeding. Symptoms may include nosebleeds, blood in urine, vomiting blood, or unusual bruising. Seek immediate medical attention if an overdose is suspected. Do not attempt to self-treat a suspected overdose.

If you miss a dose of Ticagrelor, take it as soon as you remember. However, if your next dose is almost due, skip the missed dose and resume your normal schedule. Do not take a double dose to make up for the missed one, as this increases the risk of bleeding. Maintaining a regular dosing routine is important to ensure continuous protection against heart attacks and strokes.